IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Lonza and Human Genome Sciences Sign Manufacturing Agreement

11:55 PM MDT | July 12, 2010 | Deepti Ramesh

Lonza says it has entered into an agreement with Human Genome Sciences (HGS; Rockville, MD) for the future commercial supply of Benlysta (belimumab), which is currently under regulatory review in the U.S. and Europe as a potential new treatment for systemic lupus erythematosus (SLE). Benlysta is being developed by HGS and GlaxoSmithKline (GSK; London) under a co-development and commercialization agreement entered into in 2006. GSK submitted a marketing authorization application last month to the European Medicines Agency, seeking approval to market belimumab in...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa